Dan McNamara is a life sciences executive with more than 15 years of experience across corporate strategy, business development, and enterprise operations. Prior to joining the T1D Fund, he served as Vice President of Enterprise Governance and Strategy & Business Development Operations at Bristol Myers Squibb, where he led strategic and operational functions supporting more than $100 billion in M&A and business development activity.

At BMS, Dan oversaw large-scale transformation efforts to shape corporate strategy, improve cross-functional execution, align capital deployment with long-term priorities, and accelerate portfolio decision-making across both internal and external innovation. Previously, Dan founded SmarterAdmin, a healthcare-focused management consulting firm that supported over 3,000 healthcare professionals across more than 100 academic medical centers and institutions. He also held senior roles at Columbia University Medical Center, leading initiatives in financial planning, capital allocation, resource operations, and enterprise systems strategy.

Dan holds dual degrees in Finance and Psychology from the University of Maryland and is passionate about mission-driven innovation in diseases with high unmet need, including type 1 diabetes.

Daniel Flicker joined the T1D Fund in January 2025. Prior to joining the Fund, he was a Senior Associate at Novo Holdings, where he focused on venture investments across biotech and medtech company stages and therapeutic areas, and served as a board observer for three portfolio companies.

Earlier in his career, Daniel worked in healthcare investment banking and equity research at Chardan, and in life sciences management consulting at L.E.K. Consulting.

Daniel earned his Ph.D. in Systems Biology from Harvard University, where his research focused on mitochondrial metabolism in brown fat. He holds a B.A. in Biochemistry from Columbia University.